Vaxil Bio Ltd.
VXL.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -95.60K | -80.60K | -139.30K | -188.70K | -335.30K |
| Total Depreciation and Amortization | -- | -- | -- | -- | 0.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.20K | 14.10K | 14.10K | 14.90K | 14.20K |
| Change in Net Operating Assets | -71.60K | -93.90K | -184.40K | -242.20K | -179.10K |
| Cash from Operations | -165.10K | -160.50K | -309.70K | -416.20K | -500.30K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -182.70K | -182.70K | -- | -- | -- |
| Cash from Investing | -182.70K | -182.70K | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 800.00 | -5.20K | -3.80K | -8.30K | -900.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -347.10K | -348.50K | -313.50K | -424.30K | -501.00K |